If approved, Mavenclad could offer a more patient-friendly dosing regimen than existing MS oral drugs. Biogen’s Tecfidera (dimethyl fumarate) is taken twice daily and is associated with ...
NICE’s latest decision on the drug was supported by clinical and real-world evidence demonstrating that Mavenclad can reduce MS relapse rates and slow disability progression. The agency is now ...
US pharma group Merck said the UAE Ministry of Health and Prevention has approved the registration of its Mavenclad (cladribine tablets) for the treatment of adult patients with highly active ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback